Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 17

recruiting
3 972
countries
28
conditions
2 103

467 trials match your criteria

Non-small cell lung cancer stage IIIA+1

Not yet recruiting

Study on Pembrolizumab as Maintenance Therapy for Patients with Unresectable Stage III Non-Small Cell Lung Cancer After Chemo-Radiotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Non-renal cell carcinoma of kidney+1

Not yet recruiting

Study of Pembrolizumab and Enfortumab Vedotin for Patients with Collecting Duct and Renal Medullary Carcinoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Anal cancer

Not yet recruiting

Study of Pembrolizumab with Standard Chemoradiation for Patients with Advanced Anal Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Colon cancer

Not yet recruiting

Study on Pembrolizumab and Drug Combination for Patients with Localized Colon Cancer with Specific Genetic Markers

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine

Neoplasm

Not yet recruiting

Study on Pembrolizumab, Atezolizumab, and Nivolumab with Carbon Ion Radiotherapy for Patients with Advanced Melanoma, Urothelial Carcinoma, NSCLC, or Head & Neck Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Cervical dysplasia+1

Not yet recruiting

Study on Pembrolizumab for Patients with High-Grade HPV-Related Vulvar and Cervical Lesions

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab

Uveal melanoma

Not yet recruiting

Study of Darovasertib and Crizotinib for Patients with HLA-A2 Negative Metastatic Uveal Melanoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib

Non-small cell lung cancer

Not yet recruiting

Study to Compare Zongertinib with Standard Treatment for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Haematological malignancy+1

Not yet recruiting

Study on the Safety and Effectiveness of Pembrolizumab, Favezelimab, and Vibostolimab for Children and Young Adults with Blood Cancers or Solid Tumors

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Substances:Favezelimab

Transitional cell carcinoma

Not yet recruiting

Study of BT8009 Alone or with Pembrolizumab for Patients with Advanced or Metastatic Bladder Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Avelumab

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Transitional cell carcinoma

Not yet recruiting

Study of Disitamab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer Expressing HER2

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.